Overview

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Status:
Recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

Phase:

Phase 2

Details

Lead Sponsor:

Viracta Therapeutics, Inc.

Treatments:

Valganciclovir